Sanofi Accused Of Shorting Staff For Sales Of Cancer Drug

Law360, Washington (September 19, 2013, 1:26 PM EDT) -- Two former Sanofi-Aventis US LLC sales employees hit the pharmaceutical giant with a putative class action Tuesday, claiming the company backtracked on commission agreements stemming from sales of the cancer drug Zaltrap.

Lead plaintiffs Lisa Overton and Merribeth Bazzell claimed that Sanofi refused to fully compensate Zaltrap sales representatives months after they exceeded expectations, despite repeated reassurances that the company would not change its sales incentive program.

Sanofi allegedly established and explained the “Sanofi Incentive Compensation Plan Policy” for Zaltrap sales in late August 2012, just...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

OVERTON et al v. SANOFI-AVENTIS U.S., LLC


Case Number

3:13-cv-05535

Court

New Jersey

Nature of Suit

Contract: Other

Judge

Douglas E. Arpert

Date Filed

September 17, 2013

Law Firms

Companies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.